Phase 2 Trial Closure Clears a Path for Accelerated Development of Stenoparib in Ovarian Cancer

A phase 2 trial of stenoparib in advanced recurrent ovarian cancer has been closed early to enable a follow-on trial with FDA regulatory intent.

Related Keywords

,Thomas Jensen ,Allarity Therapeutics Inc ,Allarity Therapeutics Drug Response ,Allarity Therapeutics ,Accessed May ,Ovarian Cancer ,Stenoparib ,Fda Regulatory Intent ,Trial Closure ,Phase 2 Trial ,